Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

451 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Study.
Murrell DF, Caux F, Patsatsi A, Hagino O, Rudnicka L, Vassileva S, Uzun S, Ye J, Yen K, Arora P, Gourlay SG, Joly P, Werth VP. Murrell DF, et al. Among authors: werth vp. J Invest Dermatol. 2024 Aug;144(8):1762-1771.e6. doi: 10.1016/j.jid.2024.02.023. Epub 2024 Mar 16. J Invest Dermatol. 2024. PMID: 38493933 Free article. Clinical Trial.
Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus.
Morand EF, Pike M, Merrill J, F van Vollenhoven R, Werth VP, Hobar C, Delev N, Shah V, Sharkey B, Wegman T, Catlett I, Banerjee S, Singhal S. Morand EF, et al. Among authors: werth vp. Expert Opin Investig Drugs. 2024 May;33(5):431-440. doi: 10.1080/13543784.2024.2337736. Epub 2024 May 29. Expert Opin Investig Drugs. 2024. PMID: 38807572 Free article.
Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Fiorentino D, Mangold AR, Werth VP, Christopher-Stine L, Femia A, Chu M, Musiek ACM, Sluzevich JC, Graham LV, Fernandez AP, Aggarwal R, Rieger K, Page KM, Li X, Hyde C, Rath N, Sloan A, Oemar B, Banerjee A, Salganik M, Banfield C, Neelakantan S, Beebe JS, Vincent MS, Peeva E, Vleugels RA. Fiorentino D, et al. Among authors: werth vp. Lancet. 2025 Jan 11;405(10473):137-146. doi: 10.1016/S0140-6736(24)02071-3. Lancet. 2025. PMID: 39798982 Clinical Trial.
451 results